COMPASS Pathways: Buy the FDA Momentum After COMP360 Wins and NDA Submission
COMPASS Pathways (CMPS) is a high-conviction long. Positive Phase 3 results for COMP360, accelerated regulatory momentum and an imminent NDA full submission in Q4 create a path to rapid re-pricing. The company is currently trading at ~$13.14 with a market cap near $1.77B and a strong balance-sheet profile; this trade idea lays out entry, stop and t…